ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.465,69
-0,03%
S&P 500
5.180,74
1,03%
US Dollar vs BRL
5,0764
0,00%
Bitcoin
63.367,05
0,32%
Brent Oil
83,435
-0,05%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. USOTC
  6. Revive Therapeutics Ltd (QB) (RVVTF)

  7. Revive Therapeutics Ltd (QB) (RVVTF) Notícias

RVVTF

Revive Therapeutics (QB) (RVVTF)

Revive Therapeutics Ltd (QB)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:USOTC:RVVTF
DataHoraFonteTítuloCódigoCompanhia
18/04/202211:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
12/04/202209:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
24/02/202210:35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchUSOTC:RVVTFRevive Therapeutics Ltd (QB)
16/02/202210:03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/01/202211:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
07/01/202210:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
16/11/202110:00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/09/202108:30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/08/202107:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerUSOTC:RVVTFRevive Therapeutics Ltd (QB)
12/08/202110:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
10/08/202109:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
15/07/202115:47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
28/06/202109:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/06/202109:59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
08/06/202110:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/05/202110:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripUSOTC:RVVTFRevive Therapeutics Ltd (QB)
03/05/202110:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
27/04/202110:51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/04/202109:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contUSOTC:RVVTFRevive Therapeutics Ltd (QB)
24/03/202110:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
19/03/202108:56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
26/02/202111:01InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/02/202111:53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
11/02/202110:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
27/01/202110:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/01/202111:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesUSOTC:RVVTFRevive Therapeutics Ltd (QB)
14/01/202110:30InvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityUSOTC:RVVTFRevive Therapeutics Ltd (QB)
31/12/202010:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyUSOTC:RVVTFRevive Therapeutics Ltd (QB)
23/12/202011:57InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/12/202013:05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
 Apresentando as notícias mais relevantes sobre:USOTC:RVVTF

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
MNPR3
MINUPAR ON
BOV
PRIO3
PETRORIO ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
ENAT3
ENAUTA ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados